Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
arcticnovartis
- New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session
- New ianalumab interim results from Sjögren’s Phase III extension study up to week 108 and Phase II data in systemic lupus erythematosus will be presented